JOINT FILING AGREEMENTJoint Filing Agreement • January 29th, 2010 • 683 Capital Management, LLC • Services-personal services
JOINT FILING AGREEMENTJoint Filing Agreement • March 22nd, 2019 • 683 Capital Management, LLC • Fire, marine & casualty insurance
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.01 par value, of Maiden Holdings, Ltd., a Bermuda limited company. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • July 26th, 2019 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Novus Therapeutics, Inc. dated as of July 26, 2019 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • December 22nd, 2017 • 683 Capital Management, LLC • Retail-auto dealers & gasoline stations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Class A Common Stock of Carvana Co. dated as of December 22, 2017 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 29th, 2018 • 683 Capital Management, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated November 29, 2018 (including amendments thereto) with respect to the Common Stock, $0.0001 par value, of Syndax Pharmaceuticals, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • January 22nd, 2018 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Alderyra Therapeutics, Inc. dated as of January 22, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • December 22nd, 2017 • 683 Capital Management, LLC • Radiotelephone communications
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of NII Holdings, Inc. dated as of December 22, 2017 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • October 15th, 2018 • 683 Capital Management, LLC
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Eiger BioPharmaceuticals, Inc. dated as of October 15, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • September 16th, 2019 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Zafgen, Inc. dated as of September 16, 2019 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2018 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock, $0.01 par value, of Onconova Thereapeutics, Inc. dated as of the date hereof is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • March 16th, 2018 • 683 Capital Management, LLC • Electromedical & electrotherapeutic apparatus
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Soleno Therapeutics, Inc. dated as of March 16, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • June 22nd, 2018 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Galmed Pharmaceuticals Ltd. dated as of June 22, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • July 23rd, 2018 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of SELLAS Life Sciences Group Inc. dated as of July 23, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • August 12th, 2019 • 683 Capital Management, LLC • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Adamis Pharmaceuticals Corporation dated as of August 12, 2019 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • July 26th, 2018 • 683 Capital Management, LLC • Real estate investment trusts
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of NII Holdings, Inc. dated as of July 26, 2018 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
